Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
-
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
-
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
-
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
-
ReShape Lifesciences Inc. (RSLS) to Merge with Vyome Therapeutics, Enters Asset Purchase Agreement With Biorad Medisys
-
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
-
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
-
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
-
ReShape Lifesciences Inc. (RSLS) Provides Update on 2024 Cost Reduction Plan
-
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
-
ReShape Lifesciences Inc. (RSLS) Engages Maxim Group to Identify Strategic M&A Partnership Alternatives
-
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
-
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
-
ReShape Lifesciences (RSLS) Enters Warrant Exercise Transaction for $1.2M in Gross Proceeds
-
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
-
ReShape Lifesciences (RSLS) Announces Pricing of $3 Million Public Offering
-
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
-
ReShape Lifesciences (RSLS) Prices $2.5M Offering at $3.07/sh
-
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
-
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
-
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
-
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
-
ReShape Lifesciences Inc. (RSLS) Prices Upsized $10.2 Million Underwritten Public Offering of Common Stock, Warrants
-
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
-
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
-
ReShape Lifesciences Inc. (RSLS) Announces $750,000 Registered Direct Offering
-
ReShape Lifesciences Announces $750,000 Registered Direct Offering
-
ReShape Lifesciences Announces $750,000 Registered Direct Offering
-
ReShape Lifesciences Inc. (RSLS) Announces $2.5M Warrant Exercise Transaction
-
ReShape Lifesciences Inc. (RSLS) Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds
-
ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds
-
ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds
-
ReShape Lifesciences Completes $46 Million Capital Raise With Key Institutional Shareholders
-
ReShape Lifesciences Enters into Warrant Exercise Transaction for $46.2 Million in Gross Proceeds
-
ReShape Lifesciences Completes Merger with Obalon Therapeutics
